# CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

> **NCT02277522** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 4 (actual)

## Conditions studied

- Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

## Interventions

- **BIOLOGICAL:** RNA anti-CD19 CAR T cells

## Key facts

- **NCT ID:** NCT02277522
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2016-11
- **Final completion:** 2017-06-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** unable to meet enrollment goal
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277522, "CD19 Redirected Autologous T Cells for Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02277522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*